Andreas Schatzlein PhD

Andreas has a track record of medicines development and translational research in industry and academia. As a senior scientist at the biotech start-up IDEA in Munich, he was intimately involved in the scientific, clinical and commercial development of its transdermal delivery nanotechnology products. In 1996 he joined academia at the Cancer Research UK Beatson Laboratories at the University of Glasgow. He became leader of the Cancer Research UK’s Experimental Therapeutics and Gene Medicines Group. As Head of the Analytical Services Unit he was instrumental in the introduction of good clinical laboratory practice (GCLP) standards and responsible for the analysis of pharmacokinetics and pharmacodynamics readouts in a range of Translational Clinical Trials.

Andreas research has been featured repeatedly in the media (TV, radio, print) and has been supported by the BBSRC, EPSRC, Wellcome Trust, Royal Society, Scottish Enterprise, Tenovus Scotland, CRUK, the Technology Strategy Board and FP7. Andreas is also co-founder and CEO of Nanomerics Ltd, a UCL spinout company developing pharmaceutical nanotechnology.